Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LUND, Sweden, May 27, 2016 (GLOBE NEWSWIRE) -- The Annual General Meeting of Active Biotech was held on May 26, 2016. In accordance with the Board of Directors' proposal, it was resolved that no...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The Annual General Meeting of...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotechs årsstämma hölls...
-
-
Active Biotech's Annual Report 2015 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotech's Annual Report 2015 is now...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Active Biotechs årsredovisning för 2015 finns...
-
LUND, Sweden, April 28, 2016 (GLOBE NEWSWIRE) -- Laquinimod The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod· Den kliniska fas 3-studien...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod· The clinical Phase 3 study...